Merck Says FDA Approves Update To US Product Label For WINREVAIR For Injection, 45mg, 60mg, Based On The Phase 3 HYPERION Trial
In brief
Merck’s FDA label approval for WINREVAIR in newly diagnosed PAH patients could broaden its use and improve patient outcomes.